-
Sanofi: Expected to contribute over 10 billion euros in newly launched innovative drugs by 2030
On December 8th, Shanghai, Xinhua Finance and Economics reported that Sanofi's investor research and development day was recently held. Sanofi announced 12 new molecular entities with the potential f ... -
Novo Nordisk plans to introduce weight loss oral small molecule drugs for 235 million euros
On January 23rd, Novo Nordisk announced a cooperation and licensing agreement with EraCal Therapeutics to develop and commercialize EraCal as a weight loss oral small molecule drug. It is reported th ... -
AstraZeneca and Sinopharm Group reach nearly $2 billion cardiovascular drug authorization agreement
AstraZeneca and Shiyao Group Limited have reached an exclusive licensing agreement to advance the development of a preclinical innovative small molecule lipoprotein (a) (Lp (a)) inhibitor. According ... -
Johnson&Johnson's drug Zebaike has been approved in China
On October 21st, Johnson&Johnson announced that its drug Zebeko (Nilaparivabiraterone tablets) has been officially approved by the National Medical Products Administration. As the first and only appr ... -
Lilly's Alzheimer's disease drug Kisunla approved for sale in the UK
According to Lilly, the Medicines and Medical Products Regulatory Authority (MHRA) in the UK has granted marketing authorization for its drug, donanemab, for Alzheimer's disease. Donanemab (trade nam ... -
Lilly's Alzheimer's disease drug Kisunla approved for sale in the UK
On October 26th, according to Eli Lilly, the Medicines and Medical Products Regulatory Authority (MHRA) in the UK has granted marketing authorization for its drug donanemab. Donanemab (trade name: Ki ... -
Lilly claims that the weight loss drug Mounjaro has been approved for sale in Hong Kong
On October 28, Lilly said in a statement that it had obtained the approval of the Hong Kong SAR government to sell its Tirzepatide injection (trade name: Mounjaro) through a device called Kwikpen (pr ...